Equities

Solventum Corp

Solventum Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)68.10
  • Today's Change-1.08 / -1.56%
  • Shares traded529.58k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 11 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Solventum Corp. is a global healthcare company. Its segments include Medical Surgical, Dental Solutions, Health Information Systems, and Purification and Filtration. Medical Surgical is a provider of solutions including advanced wound care, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Dental Solutions provides dental and orthodontic products include brackets, aligners, restorative cements, and bonding agents that span the life of the tooth, including products designed for preventative dental care, direct and indirect restoration, and broad orthodontic needs. Health Information Systems offers healthcare systems with software solutions, including computer-assisted physician documentation, direct-to-bill and coding automation, speech recognition, and data visualization platforms. Purification and Filtration is a provider of purification and filtration technologies including filters, purifiers, cartridges, and membranes.

  • Revenue in USD (TTM)8.21bn
  • Net income in USD1.06bn
  • Incorporated2023
  • Employees22.01k
  • Location
    Solventum CorpC/O 3M Company3M Center, Building 275-6W-02ST. PAUL 55144-1000United StatesUSA
  • Phone+1 (651) 733-1110
  • Fax+1 (302) 636-5454
  • Websitehttps://www.solventum.com/en-us/home/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Glaukos Corp341.73m-158.61m7.05bn907.00--10.57--20.62-3.20-3.206.9112.130.36421.677.55376,764.10-16.91-8.73-18.20-9.3576.5374.77-46.41-28.694.67-56.930.16--11.2611.66-35.75--14.44--
Penumbra Inc1.13bn14.23m7.48bn4.20k563.926.44172.476.600.34150.341528.9429.900.76421.075.53269,924.500.95952.321.072.6165.4563.901.263.173.77--0.02090.0024.9518.934,643.1668.609.64--
Lantheus Holdings Inc1.44bn428.48m7.51bn834.0017.717.3115.385.226.116.1120.4814.790.87758.354.581,724,234.0026.156.6929.967.7364.4957.5629.809.024.41--0.35460.0038.6530.441,063.8651.8135.48--
Repligen Corp602.35m-1.90m7.53bn1.78k--3.79109.8112.50-0.0416-0.041610.6735.530.22261.464.95337,831.80-0.07034.38-0.07825.0347.7055.43-0.315615.915.56--0.22820.00-20.3126.91-77.6420.1324.99--
Masimo Corp2.02bn79.40m7.59bn3.80k96.585.5243.483.761.471.4737.3225.730.68311.945.77530,763.202.698.653.3210.3149.2857.303.9412.031.153.300.36350.000.604219.00-43.21-15.9631.06--
Henry Schein, Inc.12.49bn352.00m8.87bn25.00k25.892.5314.060.71072.712.7195.9827.641.294.888.25499,480.003.586.095.9710.4431.6330.042.784.400.8966.850.33330.00-2.445.55-22.68-0.145621.27--
Bio Rad Laboratories Inc2.56bn-1.33bn9.30bn8.03k--1.39--3.63-47.03-47.0389.18240.390.23661.495.47319,128.80-12.249.08-12.879.6054.0255.55-51.7341.974.630.16530.15040.00-4.673.1382.43--3.83--
Globus Medical Inc2.24bn40.68m9.45bn5.00k235.122.3835.094.230.29680.296817.0229.380.62071.635.25447,306.001.136.901.307.4559.6571.731.8214.051.45455.560.0980.0053.3417.08-35.39-4.725.57--
Bruker Corp3.12bn352.10m9.65bn9.71k26.525.3919.473.092.402.4021.2411.820.63931.475.90321,386.607.218.389.5911.4050.0849.8511.2811.390.724442.630.54199.8117.149.3644.0318.9116.794.56
Teleflex Inc3.01bn264.76m11.05bn14.50k41.942.4221.233.685.595.5763.5496.760.41962.096.85207,437.103.695.864.006.4255.8654.438.8014.621.447.140.273715.846.573.97-1.4712.732.510.00
Solventum Corp8.21bn1.06bn11.76bn22.01k11.114.107.291.436.136.1347.5016.600.58173.977.36372,926.807.50--8.72--56.98--12.89--0.958410.030.7434--0.8241--0.2234------
Revvity Inc2.71bn197.34m14.83bn11.50k75.281.8823.685.481.601.3721.9063.800.19592.894.42235,499.601.434.761.595.3955.2657.197.2915.341.986.890.32996.52-16.95-0.1982-64.99-5.28-2.690.00
Insulet Corp1.87bn395.30m16.21bn3.00k42.7216.2434.438.665.415.4124.5314.240.7111.386.25624,233.3015.012.7118.153.1469.0065.8121.114.282.7187.970.58330.0030.0224.664,384.78128.77-7.63--
Avantor Inc6.83bn360.20m16.64bn14.50k46.213.0621.862.440.52950.529510.038.000.5305.375.82470,731.002.802.973.173.3533.7133.445.285.061.053.070.48480.00-7.263.51-51.52--31.17--
Data as of Oct 11 2024. Currency figures normalised to Solventum Corp's reporting currency: US Dollar USD

Institutional shareholders

26.32%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 01 Apr 202412.27m7.10%
SSgA Funds Management, Inc.as of 01 Apr 20248.96m5.19%
BlackRock Fund Advisorsas of 01 Apr 20246.91m4.00%
Davis Selected Advisers LPas of 30 Jun 20245.16m2.99%
Geode Capital Management LLCas of 30 Jun 20243.22m1.86%
Nuance Investments LLCas of 30 Jun 20242.19m1.27%
State Farm Investment Management Corp.as of 31 Mar 20242.07m1.20%
Newport Trust Co.as of 31 Mar 20241.95m1.13%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 20241.51m0.88%
Pacer Advisors, Inc.as of 31 Mar 20241.21m0.70%
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.